Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027

SKU ID : QYR-19329877 | Publishing Date : 13-Oct-2021 | No. of pages : 127

Detailed TOC of Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Hematological Malignancies Disease Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Chemotherapy
        1.2.3 Immunotherapy
        1.2.4 Targeted Therapy
        1.2.5 Radiotherapy
        1.2.6 Stem Cell Transplantation
        1.2.7 Others
    1.3 Market by Application
        1.3.1 Global Hematological Malignancies Disease Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Leukemia
        1.3.3 Lymphoma
        1.3.4 Myeloma
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Hematological Malignancies Disease Market Perspective (2016-2027)
    2.2 Hematological Malignancies Disease Growth Trends by Regions
        2.2.1 Hematological Malignancies Disease Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Hematological Malignancies Disease Historic Market Share by Regions (2016-2021)
        2.2.3 Hematological Malignancies Disease Forecasted Market Size by Regions (2022-2027)
    2.3 Hematological Malignancies Disease Industry Dynamic
        2.3.1 Hematological Malignancies Disease Market Trends
        2.3.2 Hematological Malignancies Disease Market Drivers
        2.3.3 Hematological Malignancies Disease Market Challenges
        2.3.4 Hematological Malignancies Disease Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Hematological Malignancies Disease Players by Revenue
        3.1.1 Global Top Hematological Malignancies Disease Players by Revenue (2016-2021)
        3.1.2 Global Hematological Malignancies Disease Revenue Market Share by Players (2016-2021)
    3.2 Global Hematological Malignancies Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Hematological Malignancies Disease Revenue
    3.4 Global Hematological Malignancies Disease Market Concentration Ratio
        3.4.1 Global Hematological Malignancies Disease Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Hematological Malignancies Disease Revenue in 2020
    3.5 Hematological Malignancies Disease Key Players Head office and Area Served
    3.6 Key Players Hematological Malignancies Disease Product Solution and Service
    3.7 Date of Enter into Hematological Malignancies Disease Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Hematological Malignancies Disease Breakdown Data by Type
    4.1 Global Hematological Malignancies Disease Historic Market Size by Type (2016-2021)
    4.2 Global Hematological Malignancies Disease Forecasted Market Size by Type (2022-2027)

5 Hematological Malignancies Disease Breakdown Data by Application
    5.1 Global Hematological Malignancies Disease Historic Market Size by Application (2016-2021)
    5.2 Global Hematological Malignancies Disease Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Hematological Malignancies Disease Market Size (2016-2027)
    6.2 North America Hematological Malignancies Disease Market Size by Type
        6.2.1 North America Hematological Malignancies Disease Market Size by Type (2016-2021)
        6.2.2 North America Hematological Malignancies Disease Market Size by Type (2022-2027)
        6.2.3 North America Hematological Malignancies Disease Market Size by Type (2016-2027)
    6.3 North America Hematological Malignancies Disease Market Size by Application
        6.3.1 North America Hematological Malignancies Disease Market Size by Application (2016-2021)
        6.3.2 North America Hematological Malignancies Disease Market Size by Application (2022-2027)
        6.3.3 North America Hematological Malignancies Disease Market Size by Application (2016-2027)
    6.4 North America Hematological Malignancies Disease Market Size by Country
        6.4.1 North America Hematological Malignancies Disease Market Size by Country (2016-2021)
        6.4.2 North America Hematological Malignancies Disease Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Hematological Malignancies Disease Market Size (2016-2027)
    7.2 Europe Hematological Malignancies Disease Market Size by Type
        7.2.1 Europe Hematological Malignancies Disease Market Size by Type (2016-2021)
        7.2.2 Europe Hematological Malignancies Disease Market Size by Type (2022-2027)
        7.2.3 Europe Hematological Malignancies Disease Market Size by Type (2016-2027)
    7.3 Europe Hematological Malignancies Disease Market Size by Application
        7.3.1 Europe Hematological Malignancies Disease Market Size by Application (2016-2021)
        7.3.2 Europe Hematological Malignancies Disease Market Size by Application (2022-2027)
        7.3.3 Europe Hematological Malignancies Disease Market Size by Application (2016-2027)
    7.4 Europe Hematological Malignancies Disease Market Size by Country
        7.4.1 Europe Hematological Malignancies Disease Market Size by Country (2016-2021)
        7.4.2 Europe Hematological Malignancies Disease Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Hematological Malignancies Disease Market Size (2016-2027)
    8.2 Asia-Pacific Hematological Malignancies Disease Market Size by Type
        8.2.1 Asia-Pacific Hematological Malignancies Disease Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Hematological Malignancies Disease Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Hematological Malignancies Disease Market Size by Type (2016-2027)
    8.3 Asia-Pacific Hematological Malignancies Disease Market Size by Application
        8.3.1 Asia-Pacific Hematological Malignancies Disease Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Hematological Malignancies Disease Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Hematological Malignancies Disease Market Size by Application (2016-2027)
    8.4 Asia-Pacific Hematological Malignancies Disease Market Size by Region
        8.4.1 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Hematological Malignancies Disease Market Size (2016-2027)
    9.2 Latin America Hematological Malignancies Disease Market Size by Type
        9.2.1 Latin America Hematological Malignancies Disease Market Size by Type (2016-2021)
        9.2.2 Latin America Hematological Malignancies Disease Market Size by Type (2022-2027)
        9.2.3 Latin America Hematological Malignancies Disease Market Size by Type (2016-2027)
    9.3 Latin America Hematological Malignancies Disease Market Size by Application
        9.3.1 Latin America Hematological Malignancies Disease Market Size by Application (2016-2021)
        9.3.2 Latin America Hematological Malignancies Disease Market Size by Application (2022-2027)
        9.3.3 Latin America Hematological Malignancies Disease Market Size by Application (2016-2027)
    9.4 Latin America Hematological Malignancies Disease Market Size by Country
        9.4.1 Latin America Hematological Malignancies Disease Market Size by Country (2016-2021)
        9.4.2 Latin America Hematological Malignancies Disease Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Hematological Malignancies Disease Market Size (2016-2027)
    10.2 Middle East & Africa Hematological Malignancies Disease Market Size by Type
        10.2.1 Middle East & Africa Hematological Malignancies Disease Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Hematological Malignancies Disease Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Hematological Malignancies Disease Market Size by Type (2016-2027)
    10.3 Middle East & Africa Hematological Malignancies Disease Market Size by Application
        10.3.1 Middle East & Africa Hematological Malignancies Disease Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Hematological Malignancies Disease Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Hematological Malignancies Disease Market Size by Application (2016-2027)
    10.4 Middle East & Africa Hematological Malignancies Disease Market Size by Country
        10.4.1 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Affymetrix
        11.1.1 Affymetrix Company Details
        11.1.2 Affymetrix Business Overview
        11.1.3 Affymetrix Hematological Malignancies Disease Introduction
        11.1.4 Affymetrix Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.1.5 Affymetrix Recent Development
    11.2 SkylineDx
        11.2.1 SkylineDx Company Details
        11.2.2 SkylineDx Business Overview
        11.2.3 SkylineDx Hematological Malignancies Disease Introduction
        11.2.4 SkylineDx Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.2.5 SkylineDx Recent Development
    11.3 AgenaBio
        11.3.1 AgenaBio Company Details
        11.3.2 AgenaBio Business Overview
        11.3.3 AgenaBio Hematological Malignancies Disease Introduction
        11.3.4 AgenaBio Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.3.5 AgenaBio Recent Development
    11.4 Signal Genetics
        11.4.1 Signal Genetics Company Details
        11.4.2 Signal Genetics Business Overview
        11.4.3 Signal Genetics Hematological Malignancies Disease Introduction
        11.4.4 Signal Genetics Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.4.5 Signal Genetics Recent Development
    11.5 Pfizer
        11.5.1 Pfizer Company Details
        11.5.2 Pfizer Business Overview
        11.5.3 Pfizer Hematological Malignancies Disease Introduction
        11.5.4 Pfizer Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.5.5 Pfizer Recent Development
    11.6 Roche
        11.6.1 Roche Company Details
        11.6.2 Roche Business Overview
        11.6.3 Roche Hematological Malignancies Disease Introduction
        11.6.4 Roche Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.6.5 Roche Recent Development
    11.7 Sanofi-Aventis
        11.7.1 Sanofi-Aventis Company Details
        11.7.2 Sanofi-Aventis Business Overview
        11.7.3 Sanofi-Aventis Hematological Malignancies Disease Introduction
        11.7.4 Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.7.5 Sanofi-Aventis Recent Development
    11.8 Cancer Genetics Inc
        11.8.1 Cancer Genetics Inc Company Details
        11.8.2 Cancer Genetics Inc Business Overview
        11.8.3 Cancer Genetics Inc Hematological Malignancies Disease Introduction
        11.8.4 Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.8.5 Cancer Genetics Inc Recent Development
    11.9 Illumina
        11.9.1 Illumina Company Details
        11.9.2 Illumina Business Overview
        11.9.3 Illumina Hematological Malignancies Disease Introduction
        11.9.4 Illumina Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.9.5 Illumina Recent Development
    11.10 NeoGenomics
        11.10.1 NeoGenomics Company Details
        11.10.2 NeoGenomics Business Overview
        11.10.3 NeoGenomics Hematological Malignancies Disease Introduction
        11.10.4 NeoGenomics Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.10.5 NeoGenomics Recent Development
    11.11 Exiqon
        11.11.1 Exiqon Company Details
        11.11.2 Exiqon Business Overview
        11.11.3 Exiqon Hematological Malignancies Disease Introduction
        11.11.4 Exiqon Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.11.5 Exiqon Recent Development
    11.12 Regulus Therapeutics
        11.12.1 Regulus Therapeutics Company Details
        11.12.2 Regulus Therapeutics Business Overview
        11.12.3 Regulus Therapeutics Hematological Malignancies Disease Introduction
        11.12.4 Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.12.5 Regulus Therapeutics Recent Development
    11.13 Rosetta Genomics
        11.13.1 Rosetta Genomics Company Details
        11.13.2 Rosetta Genomics Business Overview
        11.13.3 Rosetta Genomics Hematological Malignancies Disease Introduction
        11.13.4 Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.13.5 Rosetta Genomics Recent Development
    11.14 Sequenta
        11.14.1 Sequenta Company Details
        11.14.2 Sequenta Business Overview
        11.14.3 Sequenta Hematological Malignancies Disease Introduction
        11.14.4 Sequenta Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.14.5 Sequenta Recent Development
    11.15 Takeda Pharma
        11.15.1 Takeda Pharma Company Details
        11.15.2 Takeda Pharma Business Overview
        11.15.3 Takeda Pharma Hematological Malignancies Disease Introduction
        11.15.4 Takeda Pharma Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.15.5 Takeda Pharma Recent Development
    11.16 Celgene
        11.16.1 Celgene Company Details
        11.16.2 Celgene Business Overview
        11.16.3 Celgene Hematological Malignancies Disease Introduction
        11.16.4 Celgene Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.16.5 Celgene Recent Development
    11.17 Amgen
        11.17.1 Amgen Company Details
        11.17.2 Amgen Business Overview
        11.17.3 Amgen Hematological Malignancies Disease Introduction
        11.17.4 Amgen Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.17.5 Amgen Recent Development
    11.18 Ono Pharma
        11.18.1 Ono Pharma Company Details
        11.18.2 Ono Pharma Business Overview
        11.18.3 Ono Pharma Hematological Malignancies Disease Introduction
        11.18.4 Ono Pharma Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.18.5 Ono Pharma Recent Development
    11.18 Abbott
        .1 Abbott Company Details
        .2 Abbott Business Overview
        .3 Abbott Hematological Malignancies Disease Introduction
        .4 Abbott Revenue in Hematological Malignancies Disease Business (2016-2021)
        .5 Abbott Recent Development
    11.20 BMS
        11.20.1 BMS Company Details
        11.20.2 BMS Business Overview
        11.20.3 BMS Hematological Malignancies Disease Introduction
        11.20.4 BMS Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.20.5 BMS Recent Development
    11.21 Mundipharma
        11.21.1 Mundipharma Company Details
        11.21.2 Mundipharma Business Overview
        11.21.3 Mundipharma Hematological Malignancies Disease Introduction
        11.21.4 Mundipharma Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.21.5 Mundipharma Recent Development
    11.22 Novartis
        11.22.1 Novartis Company Details
        11.22.2 Novartis Business Overview
        11.22.3 Novartis Hematological Malignancies Disease Introduction
        11.22.4 Novartis Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.22.5 Novartis Recent Development
    11.23 MorphoSys
        11.23.1 MorphoSys Company Details
        11.23.2 MorphoSys Business Overview
        11.23.3 MorphoSys Hematological Malignancies Disease Introduction
        11.23.4 MorphoSys Revenue in Hematological Malignancies Disease Business (2016-2021)
        11.23.5 MorphoSys Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Figures, Tables and Charts Available in Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027

List of Tables
    Table 1. Global Hematological Malignancies Disease Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Chemotherapy
    Table 3. Key Players of Immunotherapy
    Table 4. Key Players of Targeted Therapy
    Table 5. Key Players of Radiotherapy
    Table 6. Key Players of Stem Cell Transplantation
    Table 7. Key Players of Others
    Table 8. Global Hematological Malignancies Disease Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 9. Global Hematological Malignancies Disease Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 10. Global Hematological Malignancies Disease Market Size by Regions (2016-2021) & (US$ Million)
    Table 11. Global Hematological Malignancies Disease Market Share by Regions (2016-2021)
    Table 12. Global Hematological Malignancies Disease Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 13. Global Hematological Malignancies Disease Market Share by Regions (2022-2027)
    Table 14. Hematological Malignancies Disease Market Trends
    Table 15. Hematological Malignancies Disease Market Drivers
    Table 16. Hematological Malignancies Disease Market Challenges
    Table 17. Hematological Malignancies Disease Market Restraints
    Table 18. Global Hematological Malignancies Disease Revenue by Players (2016-2021) & (US$ Million)
    Table 19. Global Hematological Malignancies Disease Market Share by Players (2016-2021)
    Table 20. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies Disease as of 2020)
    Table 21. Ranking of Global Top Hematological Malignancies Disease Companies by Revenue (US$ Million) in 2020
    Table 22. Global 5 Largest Players Market Share by Hematological Malignancies Disease Revenue (CR5 and HHI) & (2016-2021)
    Table 23. Key Players Headquarters and Area Served
    Table 24. Key Players Hematological Malignancies Disease Product Solution and Service
    Table 25. Date of Enter into Hematological Malignancies Disease Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million)
    Table 28. Global Hematological Malignancies Disease Revenue Market Share by Type (2016-2021)
    Table 29. Global Hematological Malignancies Disease Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 30. Global Hematological Malignancies Disease Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 31. Global Hematological Malignancies Disease Market Size Share by Application (2016-2021) & (US$ Million)
    Table 32. Global Hematological Malignancies Disease Revenue Market Share by Application (2016-2021)
    Table 33. Global Hematological Malignancies Disease Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 34. Global Hematological Malignancies Disease Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 35. North America Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million)
    Table 36. North America Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 37. North America Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million)
    Table 38. North America Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 39. North America Hematological Malignancies Disease Market Size by Country (2016-2021) & (US$ Million)
    Table 40. North America Hematological Malignancies Disease Market Size by Country (2022-2027) & (US$ Million)
    Table 41. Europe Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million)
    Table 42. Europe Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 43. Europe Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million)
    Table 44. Europe Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 45. Europe Hematological Malignancies Disease Market Size by Country (2016-2021) & (US$ Million)
    Table 46. Europe Hematological Malignancies Disease Market Size by Country (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million)
    Table 50. Asia-Pacific Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 51. Asia-Pacific Hematological Malignancies Disease Market Size by Region (2016-2021) & (US$ Million)
    Table 52. Asia-Pacific Hematological Malignancies Disease Market Size by Region (2022-2027) & (US$ Million)
    Table 53. Latin America Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million)
    Table 54. Latin America Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 55. Latin America Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million)
    Table 56. Latin America Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 57. Latin America Hematological Malignancies Disease Market Size by Country (2016-2021) & (US$ Million)
    Table 58. Latin America Hematological Malignancies Disease Market Size by Country (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Hematological Malignancies Disease Market Size by Type (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Hematological Malignancies Disease Market Size by Type (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Hematological Malignancies Disease Market Size by Application (2016-2021) (US$ Million)
    Table 62. Middle East & Africa Hematological Malignancies Disease Market Size by Application (2022-2027) & (US$ Million)
    Table 63. Middle East & Africa Hematological Malignancies Disease Market Size by Country (2016-2021) & (US$ Million)
    Table 64. Middle East & Africa Hematological Malignancies Disease Market Size by Country (2022-2027) & (US$ Million)
    Table 65. Affymetrix Company Details
    Table 66. Affymetrix Business Overview
    Table 67. Affymetrix Hematological Malignancies Disease Product
    Table 68. Affymetrix Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 69. Affymetrix Recent Development
    Table 70. SkylineDx Company Details
    Table 71. SkylineDx Business Overview
    Table 72. SkylineDx Hematological Malignancies Disease Product
    Table 73. SkylineDx Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 74. SkylineDx Recent Development
    Table 75. AgenaBio Company Details
    Table 76. AgenaBio Business Overview
    Table 77. AgenaBio Hematological Malignancies Disease Product
    Table 78. AgenaBio Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 79. AgenaBio Recent Development
    Table 80. Signal Genetics Company Details
    Table 81. Signal Genetics Business Overview
    Table 82. Signal Genetics Hematological Malignancies Disease Product
    Table 83. Signal Genetics Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 84. Signal Genetics Recent Development
    Table 85. Pfizer Company Details
    Table 86. Pfizer Business Overview
    Table 87. Pfizer Hematological Malignancies Disease Product
    Table 88. Pfizer Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 89. Pfizer Recent Development
    Table 90. Roche Company Details
    Table 91. Roche Business Overview
    Table 92. Roche Hematological Malignancies Disease Product
    Table 93. Roche Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 94. Roche Recent Development
    Table 95. Sanofi-Aventis Company Details
    Table 96. Sanofi-Aventis Business Overview
    Table 97. Sanofi-Aventis Hematological Malignancies Disease Product
    Table 98. Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 99. Sanofi-Aventis Recent Development
    Table 100. Cancer Genetics Inc Company Details
    Table 101. Cancer Genetics Inc Business Overview
    Table 102. Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 103. Cancer Genetics Inc Recent Development
    Table 104. Illumina Company Details
    Table 105. Illumina Business Overview
    Table 106. Illumina Hematological Malignancies Disease Product
    Table 107. Illumina Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 108. Illumina Recent Development
    Table 109. NeoGenomics Company Details
    Table 110. NeoGenomics Business Overview
    Table 111. NeoGenomics Hematological Malignancies Disease Product
    Table 112. NeoGenomics Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 113. NeoGenomics Recent Development
    Table 114. Exiqon Company Details
    Table 115. Exiqon Business Overview
    Table 116. Exiqon Hematological Malignancies Disease Product
    Table 117. Exiqon Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 118. Exiqon Recent Development
    Table 119. Regulus Therapeutics Company Details
    Table 120. Regulus Therapeutics Business Overview
    Table 121. Regulus Therapeutics Hematological Malignancies Disease Product
    Table 122. Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 123. Regulus Therapeutics Recent Development
    Table 124. Rosetta Genomics Company Details
    Table 125. Rosetta Genomics Business Overview
    Table 126. Rosetta Genomics Hematological Malignancies Disease Product
    Table 127. Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 128. Rosetta Genomics Recent Development
    Table 129. Sequenta Company Details
    Table 130. Sequenta Business Overview
    Table 131. Sequenta Hematological Malignancies Disease Product
    Table 132. Sequenta Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 133. Sequenta Recent Development
    Table 134. Takeda Pharma Company Details
    Table 135. Takeda Pharma Business Overview
    Table 136. Takeda Pharma Hematological Malignancies Disease Product
    Table 137. Takeda Pharma Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 138. Takeda Pharma Recent Development
    Table 139. Celgene Company Details
    Table 140. Celgene Business Overview
    Table 141. Celgene Hematological Malignancies Disease Product
    Table 142. Celgene Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 143. Celgene Recent Development
    Table 144. Amgen Company Details
    Table 145. Amgen Business Overview
    Table 146. Amgen Hematological Malignancies Disease Product
    Table 147. Amgen Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 148. Amgen Recent Development
    Table 149. Ono Pharma Company Details
    Table 150. Ono Pharma Business Overview
    Table 151. Ono Pharma Hematological Malignancies Disease Product
    Table 152. Ono Pharma Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 153. Ono Pharma Recent Development
    Table 154. Abbott Company Details
    Table 155. Abbott Business Overview
    Table 156. Abbott Hematological Malignancies Disease Product
    Table 157. Abbott Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 158. Abbott Recent Development
    Table 159. BMS Company Details
    Table 160. BMS Business Overview
    Table 161. BMS Hematological Malignancies Disease Product
    Table 162. BMS Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 163. BMS Recent Development
    Table 164. Mundipharma Company Details
    Table 165. Mundipharma Business Overview
    Table 166. Mundipharma Hematological Malignancies Disease Product
    Table 167. Mundipharma Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 168. Mundipharma Recent Development
    Table 169. Novartis Company Details
    Table 170. Novartis Business Overview
    Table 171. Novartis Hematological Malignancies Disease Product
    Table 172. Novartis Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 173. Novartis Recent Development
    Table 174. MorphoSys Company Details
    Table 175. MorphoSys Business Overview
    Table 176. MorphoSys Hematological Malignancies Disease Product
    Table 177. MorphoSys Revenue in Hematological Malignancies Disease Business (2016-2021) & (US$ Million)
    Table 178. MorphoSys Recent Development
    Table 179. Research Programs/Design for This Report
    Table 180. Key Data Information from Secondary Sources
    Table 181. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Hematological Malignancies Disease Market Share by Type: 2020 VS 2027
    Figure 2. Chemotherapy Features
    Figure 3. Immunotherapy Features
    Figure 4. Targeted Therapy Features
    Figure 5. Radiotherapy Features
    Figure 6. Stem Cell Transplantation Features
    Figure 7. Others Features
    Figure 8. Global Hematological Malignancies Disease Market Share by Application: 2020 VS 2027
    Figure 9. Leukemia Case Studies
    Figure 10. Lymphoma Case Studies
    Figure 11. Myeloma Case Studies
    Figure 12. Others Case Studies
    Figure 13. Hematological Malignancies Disease Report Years Considered
    Figure 14. Global Hematological Malignancies Disease Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 15. Global Hematological Malignancies Disease Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 16. Global Hematological Malignancies Disease Market Share by Regions: 2020 VS 2027
    Figure 17. Global Hematological Malignancies Disease Market Share by Regions (2022-2027)
    Figure 18. Global Hematological Malignancies Disease Market Share by Players in 2020
    Figure 19. Global Top Hematological Malignancies Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies Disease as of 2020
    Figure 20. The Top 10 and 5 Players Market Share by Hematological Malignancies Disease Revenue in 2020
    Figure 21. Global Hematological Malignancies Disease Revenue Market Share by Type (2016-2021)
    Figure 22. Global Hematological Malignancies Disease Revenue Market Share by Type (2022-2027)
    Figure 23. North America Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. North America Hematological Malignancies Disease Market Share by Type (2016-2027)
    Figure 25. North America Hematological Malignancies Disease Market Share by Application (2016-2027)
    Figure 26. North America Hematological Malignancies Disease Market Share by Country (2016-2027)
    Figure 27. United States Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Canada Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. Europe Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. Europe Hematological Malignancies Disease Market Share by Type (2016-2027)
    Figure 31. Europe Hematological Malignancies Disease Market Share by Application (2016-2027)
    Figure 32. Europe Hematological Malignancies Disease Market Share by Country (2016-2027)
    Figure 33. Germany Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. France Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. U.K. Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Italy Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Russia Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Nordic Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Asia-Pacific Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Asia-Pacific Hematological Malignancies Disease Market Share by Type (2016-2027)
    Figure 41. Asia-Pacific Hematological Malignancies Disease Market Share by Application (2016-2027)
    Figure 42. Asia-Pacific Hematological Malignancies Disease Market Share by Region (2016-2027)
    Figure 43. China Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Japan Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. South Korea Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Southeast Asia Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. India Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Australia Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Latin America Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Latin America Hematological Malignancies Disease Market Share by Type (2016-2027)
    Figure 51. Latin America Hematological Malignancies Disease Market Share by Application (2016-2027)
    Figure 52. Latin America Hematological Malignancies Disease Market Share by Country (2016-2027)
    Figure 53. Mexico Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Brazil Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Middle East & Africa Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Middle East & Africa Hematological Malignancies Disease Market Share by Type (2016-2027)
    Figure 57. Middle East & Africa Hematological Malignancies Disease Market Share by Application (2016-2027)
    Figure 58. Middle East & Africa Hematological Malignancies Disease Market Share by Country (2016-2027)
    Figure 59. Turkey Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Saudi Arabia Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 61. UAE Hematological Malignancies Disease Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 62. Affymetrix Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 63. SkylineDx Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 64. AgenaBio Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 65. Signal Genetics Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 66. Pfizer Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 67. Roche Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 68. Sanofi-Aventis Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 69. Cancer Genetics Inc Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 70. Illumina Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 71. NeoGenomics Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 72. Exiqon Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 73. Regulus Therapeutics Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 74. Rosetta Genomics Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 75. Sequenta Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 76. Takeda Pharma Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 77. Celgene Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 78. Amgen Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 79. Ono Pharma Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 80. Abbott Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 81. BMS Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 82. Mundipharma Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 83. Novartis Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 84. MorphoSys Revenue Growth Rate in Hematological Malignancies Disease Business (2016-2021)
    Figure 85. Bottom-up and Top-down Approaches for This Report
    Figure 86. Data Triangulation
    Figure 87. Key Executives Interviewed

Keyplayers in Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027

Affymetrix
SkylineDx
AgenaBio
Signal Genetics
Pfizer
Roche
Sanofi-Aventis
Cancer Genetics Inc
Illumina
NeoGenomics
Exiqon
Regulus Therapeutics
Rosetta Genomics
Sequenta
Takeda Pharma
Celgene
Amgen
Ono Pharma
Abbott
BMS
Mundipharma
Novartis
MorphoSys

Request Sample

Pre-order Enquiry

Request Discount

Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027

Detailed TOC of Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027

List of Figures, Tables and Charts Available in Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027

Keyplayers in Global Hematological Malignancies Disease Market Size, Status and Forecast 2021-2027

Our Clients